Cancer Family
Malignant Neoplasm
CI-CAN-00000025CAExplore in graph →
20,126 active trials259 approved drugs3,742 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000025CAExplore in graph →
Clinical trials
90,710 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11,169)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03698994 | Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 2 | Sep 21, 2026 | clinicaltrials |
| NCT04032418 | Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 9 | Roswell Park Cancer InstituteOTHER | 1 | Sep 21, 2026 |
| clinicaltrials |
| NCT04084730 | Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer | recruiting | Phase 2 | 280 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04104893 | A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation(CHOMP) | active not recruiting | Phase 2 | 40 | VA Office of Research and DevelopmentFED | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04216316 | Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer | active not recruiting | Phase 1 / Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04335682 | Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide(ARACOG) | completed | Phase 2 | 111 | Alliance Foundation Trials, LLC.OTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04464759 | A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma(LIMIT) | active not recruiting | Phase 1 / Phase 2 | 41 | Ravi Amaravadi, MDOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04506554 | A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer | active not recruiting | Phase 2 | 81 | Fox Chase Cancer CenterOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04523428 | REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL) | recruiting | Phase 2 | 60 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 3 | Sep 21, 2026 | clinicaltrials |
| NCT04534205 | A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1(AHEAD-MERIT) | active not recruiting | Phase 2 / Phase 3 | 358 | BioNTech SEINDUSTRY | 21 | Sep 21, 2026 | clinicaltrials |
| NCT04543071 | Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma | active not recruiting | Phase 2 | 118 | Columbia UniversityOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04601584 | GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL | terminated | Phase 1 / Phase 2 | 14 | AO GENERIUMINDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04644068 | Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies(PETRA) | active not recruiting | Phase 1 / Phase 2 | 702 | AstraZenecaINDUSTRY | 14 | Sep 21, 2026 | clinicaltrials |
| NCT04661137 | A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma | recruiting | Phase 2 | 96 | Hackensack Meridian HealthOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04734262 | A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)(SPARK) | active not recruiting | Phase 2 | 98 | Fudan UniversityOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04935684 | Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation(TMF-Allo) | recruiting | Phase 2 | 150 | University Hospital, Clermont-FerrandOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04977375 | Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma | recruiting | Phase 1 / Phase 2 | 10 | Chirag G. PatilOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05172258 | Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck | active not recruiting | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05296070 | Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma | recruiting | Phase 2 | 50 | University of MiamiOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05297903 | XmAb20717 in Advanced Biliary Tract Cancers | completed | Phase 2 | 27 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05521412 | EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&T(VIOLET) | recruiting | Phase 1 / Phase 2 | 66 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05550415 | The Role of Simvastatin in The Epithelial-Mesenchymal Transition Process of Breast Cancer | recruiting | Phase 2 | 26 | Universitas IndonesiaOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05578326 | Study of Trilaciclib and Lurbinectidin | recruiting | Phase 2 | 30 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05878288 | Deep sequencIng in Cutaneous Squamous CEll caRciNomas(DISCERN) | active not recruiting | Phase 2 | 11 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05904080 | Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer | suspended | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05920798 | Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer(FRAPPE) | active not recruiting | Phase 1 / Phase 2 | 38 | Mayo ClinicOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06029309 | Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma(ZANU-TAFA) | recruiting | Phase 1 / Phase 2 | 27 | Alvaro Alencar, MDOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06040099 | A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE(EMERALD-Y90) | active not recruiting | Phase 2 | 58 | AstraZenecaINDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06114511 | A Study of BL-M07D1 in Patients With HER2-Overexpressing or HER2-Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer | active not recruiting | Phase 1 / Phase 2 | 78 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06176989 | Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors | recruiting | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06329869 | Sacituzumab Govitecan for Advanced Esophageal Squamous Cell Carcinoma(SG-ESCC) | recruiting | Phase 2 | 35 | National Taiwan University HospitalOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06349590 | Manipulation of the Gut Microbiome by a Standardized Preoperative Diet to Prevent Colorectal Cancer Recurrence and Metastasis Following Surgery(DIET) | recruiting | Phase 1 / Phase 2 | 80 | University of ChicagoOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06375915 | Precision Medicine in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization and Combined Biological Therapy(PM-CARE) | recruiting | Phase 2 | 33 | Francesco De CobelliOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06379360 | Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients | active not recruiting | Phase 2 | 60 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06745882 | Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC | recruiting | Phase 2 | 318 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06773910 | BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)(TIGOS-LS) | active not recruiting | Phase 2 | 250 | SCRI Development Innovations, LLCOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06781567 | Clinical Trial of HG146 Administered to Participants With Adenoid Cystic Carcinoma(HG146) | recruiting | Phase 2 | 140 | HitGen Inc.INDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06804655 | Pharmacoscopy for Patients With Refractory Primary Brain Tumors(EViDENCE-BT) | recruiting | Phase 2 | 40 | University of ZurichOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06838676 | ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas | recruiting | Phase 2 | 60 | Nationwide Children's HospitalOTHER | 5 | Sep 21, 2026 | clinicaltrials |
| NCT06925724 | A Study of Ivonescimab in People With Endometrial and Cervical Cancers | recruiting | Phase 2 | 50 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06980077 | Ivonescimab for the Treatment of Thymic Cancer | recruiting | Phase 2 | 25 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06997081 | ERd Combination Treatment in Newly Diagnosed Multiple Myeloma (ADVANCE 2.0) | recruiting | Phase 2 | 104 | University of MiamiOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07096778 | Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma(DOMMINO-1) | recruiting | Phase 2 | 100 | CellCentric Ltd.INDUSTRY | 2 | Sep 21, 2026 | clinicaltrials |
| NCT07162480 | Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Carcinoma Subtype I (ACC-I) | recruiting | Phase 2 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07200141 | Simultaneous Boost in Neoadjuvant Radiotherapy for Rectal Cancer(SIB-NCRT) | recruiting | Phase 2 | 156 | Peking Union Medical College HospitalOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07234981 | PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer | recruiting | Phase 2 | 54 | University of NebraskaOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07495124 | IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence | recruiting | Phase 2 | 26 | University of WashingtonOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07629960 | A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations | recruiting | Phase 1 / Phase 2 | 265 | Blueprint Medicines CorporationINDUSTRY | 2 | Sep 21, 2026 | clinicaltrials |
| NCT07639138 | Lenalidomide Plus Targeted Therapy and Immunotherapy for Refractory HCC | recruiting | Phase 2 | 32 | Shunda DuOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07693751 | A Study to Assess Safety and Efficacy of SOT109 in Patients With Advanced Unresectable or Metastatic Colorectal Cancer | recruiting | Phase 1 / Phase 2 | 100 | SOTIO Biotech a.s.INDUSTRY | 2 | Sep 21, 2026 | clinicaltrials |
Data updated 6 days agoSource updated Sep 21, 2026source: clinicaltrials